| Name | Title | Contact Details |
|---|
Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases. -We seek technologies or targets designed to predict, preempt or intervene before immune disease begins, re-appears or progresses. -We are creating a new biopharmaceutical category for autoimmunity. We leverage a transformational drug development strategy that sources, repositions and advances candidates that: -Target the interception or prevention of immune-mediated disease -Have been underdeveloped or deprioritized because of insufficient clinical trial efficacy or for strategic reasons -Have demonstrated proof-of-mechanism by preventing or intercepting immunopathologic pathways We believe that our deep understanding of immune-mediated pathophysiology, experience in translational medicine, and expertise in the design of rapid go/no-go clinical trials enables us to identify and evaluate potential therapeutic candidates for acquisition or in-licensing.
Pioneering the next generation of non-viral gene therapy - by tackling more diseases, more precisely and in a more personalized way.
Kamiya Biomedical Company is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
GFI LAB is a Rockwood, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lybradyn Inc is a Oak Brook, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.